Other
AAA manufactures and commercializes PET and SPECT nuclear medicine imaging products for the treatment of oncology and inflammatory diseases... Read more
AAA manufactures and commercializes PET and SPECT nuclear medicine imaging products for the treatment of oncology and inflammatory diseases... Read more
News
Dec 10, 2024
Pharmaceutical Processing World
Advanced Accelerator Applications: Siemens Healthineers acquires Novartis molecular imaging business
Aug 14, 2022
Medthority
Advanced Accelerator Applications: MHRA grants marketing authorisation for radioligand therapy Pluvicto (lutetium (177 Lu) vipivotide tetraxetan) in advanced prostate cancer in Great Britain. Novartis + Advanced Accelerator Applications.
Apr 29, 2022
Advanced Accelerator Applications Youtube Channel
Advanced Accelerator Applications posted a video "Neuroendocrine Cancer - Support systems and patient connection" on YOUTUBE
Apr 29, 2022
Advanced Accelerator Applications Youtube Channel
Advanced Accelerator Applications posted a video "Misconceptions of the patient profile of neuroendocrine cancer" on YOUTUBE
Apr 29, 2022
Advanced Accelerator Applications Youtube Channel
Advanced Accelerator Applications posted a video "Attitudes toward neuroendocrine cancer" on YOUTUBE
Apr 29, 2022
Advanced Accelerator Applications Youtube Channel
Advanced Accelerator Applications posted a video "Route to diagnosis of neuroendocrine cancer and understanding symptoms" on YOUTUBE
Apr 08, 2022
PharmaTimes
Advanced Accelerator Applications: UK patients granted early access for radioligand therapy in advanced prostate cancer
Mar 04, 2022
Advanced Accelerator Applications Youtube Channel
Advanced Accelerator Applications posted a video "Women in Oncology" on YOUTUBE
Sep 22, 2021
PR Newswire
Press Release: Advanced Accelerator Applications : Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals
Jul 20, 2021
Drug Discovery and Development
Advanced Accelerator Applications: Lutathera supports improved survival for patients with neuroendocrine tumors
